Sab bio ceo to participate in fireside chat at 2024 cantor global healthcare conference

Miami, sept. 13, 2024 (globe newswire) -- sab bio (nasdaq: sabs) (the “company” or “sab”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of t1d, today announced that chairman and ceo samuel j. reich will be participating in a fireside chat at the 2024 cantor global healthcare conference, september 17-19th, 2024.
SABS Ratings Summary
SABS Quant Ranking